NDATOPICALSOLUTION
Approved
Jul 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
CHG SCRUB (chlorhexidine gluconate) by Johnson & Johnson is clinical pharmacology periogard® (chlorhexidine gluconate oral rinse usp, 0. First approved in 1986.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHG SCRUB is a topical chlorhexidine gluconate 0.12% oral rinse solution approved by FDA in 1986 for antimicrobial oral cavity activity. It reduces bacterial plaque counts by 54-97% through broad-spectrum activity against aerobic and anaerobic organisms, with approximately 30% of the active ingredient retained in the oral cavity for slow, prolonged release. The drug is poorly absorbed systemically, with minimal plasma levels and primarily fecal excretion, making it a low-toxicity local therapeutic.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling potential team restructuring and focus shift to cost management and generic transition planning.
Mechanism of Action
CLINICAL PHARMACOLOGY PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) provides antimicrobial activity during oral rinsing. The clinical significance of chlorhexidine gluconate oral rinse's antimicrobial activities is not clear. Microbiological sampling of plaque has shown a general…
Indications
Worked on CHG SCRUB at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.